Takeda officer reports initial share ownership

Takeda Pharmaceutical Co Ltd executive Lauren Rusckowski Duprey reports her initial beneficial ownership of 168,513 American Depositary Shares.

Accepted by SEC EDGAR 03/18/2026 - 06:07 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Takeda Pharmaceutical Co Ltd executive Lauren Rusckowski Duprey reports her initial beneficial ownership of 168,513 American Depositary Shares. This includes 86,772 restricted stock units, each representing a right to receive one share. The RSUs vest in stages: 40,668 shares on July 1, 2026, 30,488 on July 1, 2027, and 15,616 on July 1, 2028, reflecting a multi-year equity compensation package aligned with her role as Chief HR Officer.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Duprey Lauren Rusckowski

Role Chief HR Officer

Type	Security	Shares	Price	Value
Holding	American Depositary Shares	--	--	--

Holdings: American Depositary Shares — 168,513 shares (Direct)

Footnotes (1)

1. F1. Includes 86,772 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (40,668 shares), July 1, 2027 (30,488 shares) and July 1, 2028 (15,616 shares).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Takeda (TAK) Form 3 for Lauren Rusckowski Duprey disclose?

The Form 3 discloses Chief HR Officer Lauren Rusckowski Duprey’s initial beneficial ownership in Takeda, totaling 168,513 American Depositary Shares. This figure includes a substantial grant of restricted stock units that vest over three years, illustrating the equity-based component of her compensation.

How many Takeda (TAK) shares does the Chief HR Officer initially hold?

Lauren Rusckowski Duprey is reported as beneficially owning 168,513 American Depositary Shares of Takeda. This total combines currently held shares and 86,772 restricted stock units that convert into shares as they vest, providing long-term alignment with the company’s performance and retention goals.

How many restricted stock units does Takeda (TAK) grant to its Chief HR Officer?

The filing notes that Lauren Rusckowski Duprey holds 86,772 restricted stock units. Each RSU represents a contingent right to receive one American Depositary Share of Takeda, forming a significant part of her long-term incentive compensation tied to continued service and vesting milestones.

What is the vesting schedule for Takeda (TAK) Chief HR Officer RSUs?

Her restricted stock units vest in three tranches: 40,668 shares on July 1, 2026, 30,488 shares on July 1, 2027, and 15,616 shares on July 1, 2028. This staggered schedule encourages multi-year retention and links compensation to ongoing service with the company.

What type of security is reported in Takeda (TAK) Chief HR Officer’s Form 3?

The Form 3 reports beneficial ownership of American Depositary Shares of Takeda. It also specifies that each restricted stock unit held by Lauren Rusckowski Duprey corresponds to one American Depositary Share, clarifying the direct share equivalence of her equity awards upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Duprey Lauren Rusckowski

(Last) (First) (Middle)

45-55 HAYDEN AVE.

(Street)

LEXINGTON MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief HR Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	168,513(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 86,772 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (40,668 shares), July 1, 2027 (30,488 shares) and July 1, 2028 (15,616 shares).

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Lauren Duprey	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)